Experimental drug given to Trump to treat covid-19 wins FDA clearance



Regeneron’s drug is a cocktail of two monoclonal antibodies, called casirivimab and imdevimab. The FDA said in authorizing the cocktail that it may be effective in treating mild to moderate covid-19 in adults and children 12 or older, and is indicated for those at high risk of developing severe illness. Doctors hope the drugs will keep those patients from being hospitalized.

But as with the Lilly treatment, the Regeneron drug is a biological product that is complicated and time-consuming to make; initially, it will be in short supply. The shortages, coupled with the complexities of administering the intravenous medication, have raised concerns about whether people with the greatest need will be able to get it.

Regeneron executives said on the company’s earnings call in early November that they project having enough doses for 80,000 patients by the end of November, and 300,000 total doses by the end of January.

Trump received an infusion of Regeneron’s investigational drug Oct. 2 after he tested positive for the novel coronavirus and began showing symptoms of covid-19. He received the drug through a compassionate-use program that allows people to get unapproved drugs.

In tweets and videos after he was released from the hospital, Trump inaccurately described the Regeneron drug as a cure and pressed the FDA to quickly clear the medication. It was several weeks, however, before the agency took action.

Housing and Urban Development Secretary Ben Carson disclosed on Facebook on Friday that he had also been cleared to receive the Regeneron drug for covid-19, through Trump’s intervention, “which I am convinced saved my life.” Chris Christie, the former Republican governor of New Jersey, received access to the Lilly drug during his bout with the disease.

Monoclonal antibodies, which are concocted in laboratories, are proteins that mimic the immune system’s ability to attack the virus. Regeneron’s covid-19 drug is manufactured in cells from genetically engineered hamsters.

In a clinical trial, the Regeneron drug reduced hospitalizations or emergency room visits when given to people at high risk of developing severe disease. It was also shown to reduce the amount of virus in people’s bodies. The safety and effectiveness of the drug will continue to be studied. It is not authorized for use in hospitalized patients.

In a study published Oct. 28 in the New England Journal of Medicine, researchers said the Lilly cocktail lowered the risk of follow-up medical visits and reduced levels of virus in people with mild to moderate symptoms of covid-19.

The progress on monoclonal antibodies comes as pharmaceutical and biotech companies are racing to produce coronavirus vaccines. Pfizer and Moderna might get emergency clearance for their vaccines by year’s end; Pfizer applied for FDA authorization Friday. But it will take months to vaccinate the population of the United States, much less the world, and the shots may not work for everyone. The antibody treatments can play an important role in making the disease less dangerous.

Still, if the pandemic keeps raging, the treatments will be in short supply. Unlike conventional pills, these drugs are synthesized by living organisms in specialized reactors, at a biological pace that can’t be rushed. A worldwide scramble to find capacity to make the drugs is underway, with companies striking deals with competitors to increase their manufacturing capabilities.

Through Operation Warp Speed, the Trump administration effort to speed up treatments and vaccines, the government has bought 300,000 doses each from Lilly and Regeneron at a cost of about $1,250 and $1,500 per dose, respectively, with an option to buy hundreds of thousands more. But that comes as the nation is approaching 200,000 new coronavirus cases each day.

In a sign of how quickly the supply could be used up as the pandemic surges across the country, 40 percent of the doses of Lilly’s bamlanivimab has already been allocated to states.

Because of the limited supply, the number of doses each state receives will be determined by the number of confirmed cases and hospitalizations in a given week, federal officials said.

In a recent briefing, Health and Human Services Secretary Alex Azar said the antibody treatments have “the potential to save thousands of lives and significantly reduce the disease’s burden on the health-care system.”

Where the antibody drugs will be administered is not clear, particularly because covid-19 patients are contagious and can’t be given the drug at established infusion clinics alongside people with compromised immune systems.

“You can’t send them to places where cancer patients are being treated,” said Mark McClellan, director of the Duke-Margolis Center for Health Policy and a former FDA commissioner. He said that many hospital systems have extra space they could dedicate to the antibody treatments, or could set up pop-up centers. Home-infusion providers such as CVS could administer the drug in nursing homes and people’s residences, he said.

Because of the expected shortages, doctors have expressed concerns that the medicines won’t find their way to patients who need them most, especially in disadvantaged communities.

Trump administration officials at the recent coronavirus task force briefing promised to distribute the treatment fairly and swiftly, basing distribution on a strategy similar to what is used for remdesivir, an antiviral drug for hospitalized patients. The administration’s rollout of remdesivir was plagued by problems in its early phases, including sending doses to hospitals with no eligible patients, but officials said they had learned from those mistakes.

— William Wan contributed to this report.



First Published at www.washingtonpost.com on 2020-11-22 07:07:14

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to Top